|
|
Article: NewCo News: Bioenergetics Sets 'Cornerstone' of Drug Development Approach.
- Article from:
- BIOWORLD Today
- Article date:
- October 19, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Assistant Managing Editor
It's a story familiar to the biotech industry: Promising-sounding candidates get through Phase I testing - sometimes even Phase II proof of concept - and then implode, leaving researchers and investors alike scratching their heads.
"The question we ask ourselves is 'Why do bad things happen to good drugs?'" said Robert Shorr, CEO at Cornerstone Pharmaceuticals Inc.
He and a group of other serial entrepreneurs had a few ideas when they established the Cranbury, N.J.-based company in 2002 - "with our own money and a lot of wishful thinking," Shorr said. It seemed that there were two major stumbling blocks in cancer drug ...